Flindr Therapeutics develops first-in-class small molecule inhibitors targeting oncogenic driver RNF31 for precision cancer treatment, utilizing its ImmunoGram Drug Discovery Engine to identify novel drug targets in cancer and immune cells. The company aims to enhance treatment efficacy and patient outcomes in oncology by advancing a pipeline of innovative therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers lack effective targeted therapies, leading to poor patient outcomes. Identifying novel drug targets and developing specific inhibitors remains a significant challenge in oncology.
Solution
Flindr Therapeutics is developing first-in-class small molecule inhibitors targeting oncogenic drivers, such as RNF31, for precision cancer treatment. The company utilizes its ImmunoGram Drug Discovery Engine to identify novel drug targets in cancer and immune cells. By focusing on disruptive cancer science, Flindr aims to create transformative treatments that enhance treatment efficacy and patient outcomes in oncology.
Target Audience
The primary target audience includes oncology researchers and clinicians seeking innovative and targeted therapies for cancer treatment.
Features
- Development of first-in-class small molecule inhibitors
- Targeting of oncogenic drivers like RNF31
- ImmunoGram Drug Discovery Engine for novel target identification
- Focus on precision treatment of cancer